The global Stereotactic Radiation Therapy Market is expected to grow at a significant rate in the coming years, driven by several factors such as increases prevalence of cancers and growing demand for personalized treatment option. The global market currently stands at US$ 3.7 Billion in 2022, and it is further projected to expand at a CAGR of 7.3% over the forecast period (2023-2033).
- According to the American Cancer Society, about 24,810 malignant tumors of the spinal cord or brain will be detected in the United States in 2023.
Stereotactic radiation therapy provides good tumor control rates while delivering precise doses. In comparison to conventional radiation therapy, it allows for larger radiation doses to be provided in fewer treatment sessions. This leads to better outcomes, such as higher tumor control rates and higher survival rates for some malignancies. The possibility of shorter treatment sessions and fewer side effects leads to the growing use of stereotactic radiation therapy.
Discover The Pathway To Innovation And Prosperity With Our Sample Report – Get It Now! https://www.futuremarketinsights.com/reports/sample/rep-gb-7842
Stereotactic radiation therapy is a non-invasive or minimally invasive therapeutic option that, in some situations, avoids the need for surgery. It can be used to treat both primary and metastatic tumors, offering a non-invasive alternative to invasive methods. Stereotactic radiation therapy is appealing to patients and physicians due to its ability to deliver targeted radiation without requiring open surgery.
Leading players in this market are continuing to hold the global market share by promoting their product and associated benefits. By improving state-of-the-art technology in the stereotactic radiation systems, companies are offering optimized treatment plans and delivery of radiation therapy.
Key Takeaways from Market Study
- By technology, linear accelerator radiosurgery systems accounts for US$ 2.5 billion in 2022 owed to targeted therapy and lesser adverse effect.
- By indication, CNS cancer accounts for more than0% of the market share globally in 2022. Women have a slightly higher likelihood of acquiring any form of brain or spinal cord tumor than males, while men have a little higher risk of developing a malignant tumor. Thus, for non-surgical CNS cancer treatment option, the SRT is in high demand.
- Hospitals held around 2% of the global market share in 2022. This can be ascribed to the fact that large population globally suffers from various diseases, which can be adequately identified in this setting with qualified assistance.
- By region, North America held dominant share in world in 2022. The U.S. leads in this region with high prevalence of cancer and high requirement of radiation therapy.
“The growing cancer burden and increase in adoption of personalized therapy contribute to higher demand for stereotactic radiation therapy systems.” says an analyst of Future Market Insights.
Market Competition
The stereotactic radiation therapy market is highly competitive, with key players like Ion Beam Applications (IBA), Elekta and Sumitomo Heavy Industries. These companies are constantly participating partnerships, award competition with their products and launching new products to gain a larger market share, with a focus on affordability, convenience, and effectiveness.
- In March, 2023, a research partnership has been started by IBA (Ion Beam Applications S.A., EURONEXT) for the creation of the ConformalFLASH clinical proton treatment system.
- In June, 2023, the choice to invest in Alpha Fusion Inc. (“AF”), a producer of radiopharmaceuticals based on astatine for targeted alpha therapy (“TAT”), was made official by Sumitomo Heavy Industries, Ltd.
What Does the Report Cover?
Future Market Insights offers a unique perspective and actionable insights on the stereotactic radiation therapy market in its latest study, presenting a historical demand assessment of 2017 – 2022 and projections for 2023 – 2033. The global stereotactic radiation therapy market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader
The analysis is based on technology (linear accelerator radiosurgery systems, GammaKnife radiosurgery systems, proton beam therapy, and CyberKnife), indication (CNS cancer, prostate cancer, head and neck, breast cancer, lung cancer, and others), and end user (hospitals, imaging centers, cancer research centers and oncological treatment centers), across seven key regions around the world.
Key Companies Profiled:
- Mevion Medical Systems, Inc.
- Hitachi, Ltd. (Mitsubishi Electric Corporation)
- Accuray Incorporated
- MASEP Medical Science & Technology Development (Shenzhen) Co
- Akesis, Inc
- Elekta
- Siemens Healthineers AG (Varian Medical Systems, Inc.)
- Ion Beam Applications
- ProTom International
- Pronova Solutions
- Sumitomo Heavy Industries, Ltd.
- Provision Cares
- Optivus Proton Therapy Inc.
- Advanced Oncotherapy
- Sun Nuclear Corporation
- B dot Medical Inc. (partnered with Toshiba)
Key Market Segments Covered in the Stereotactic Radiation Therapy Industry Research
By Technology:
- Linear Accelerator Radiosurgery Systems
- GammaKnife Radiosurgery Systems
- Proton Beam Therapy
- CyberKnife
By Indication:
- CNS Cancer
- Prostate Cancer
- Head and Neck
- Breast Cancer
- Lung Cancer
- Other
By End User:
- Hospitals
- Imaging Centers
- Cancer Research Centers
- Oncological Treatment Centers
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
